These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease. Gao F; Huang JF; Zheng KI; Pan XY; Ma HL; Liu WY; Byrne CD; Targher G; Li YY; Chen YP; Chan WK; Zheng MH J Gastroenterol Hepatol; 2020 Oct; 35(10):1804-1812. PubMed ID: 32246876 [TBL] [Abstract][Full Text] [Related]
7. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. Woreta TA; Van Natta ML; Lazo M; Krishnan A; Neuschwander-Tetri BA; Loomba R; Mae Diehl A; Abdelmalek MF; Chalasani N; Gawrieh S; Dasarathy S; Vuppalanchi R; Siddiqui MS; Kowdley KV; McCullough A; Terrault NA; Behling C; Kleiner DE; Fishbein M; Hertel P; Wilson LA; Mitchell EP; Miriel LA; Clark JM; Tonascia J; Sanyal AJ; PLoS One; 2022; 17(4):e0266859. PubMed ID: 35427375 [TBL] [Abstract][Full Text] [Related]
8. acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study. Wu XX; Zheng KI; Boursier J; Chan WK; Yilmaz Y; Romero-Gómez M; El Kassas M; Targher G; Byrne CD; Huang ZM; Zheng MH EClinicalMedicine; 2021 Nov; 41():101145. PubMed ID: 34646997 [TBL] [Abstract][Full Text] [Related]
9. Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 Patients. Canivet CM; Zheng MH; Qadri S; Vonghia L; Chuah KH; Costentin C; George J; Armandi A; Adams LA; Lange NF; Blanchet O; Moal V; Younes R; Roux M; Chan WK; Sturm N; Eslam M; Bugianesi E; Wang Z; Dufour JF; Francque S; Yki-Järvinen H; Zheng KI; Boursier J Clin Gastroenterol Hepatol; 2023 Nov; 21(12):3097-3106.e10. PubMed ID: 37031715 [TBL] [Abstract][Full Text] [Related]
10. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M; Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161 [TBL] [Abstract][Full Text] [Related]
11. Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States. Ciardullo S; Carbone M; Invernizzi P; Perseghin G Diabetes Res Clin Pract; 2023 May; 199():110679. PubMed ID: 37094749 [TBL] [Abstract][Full Text] [Related]
12. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort. De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068 [TBL] [Abstract][Full Text] [Related]
13. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population. Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833 [TBL] [Abstract][Full Text] [Related]
14. Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese. Ooi GJ; Burton PR; Doyle L; Wentworth JM; Bhathal PS; Sikaris K; Cowley MA; Roberts SK; Kemp W; O'Brien PE; Brown WA Obes Surg; 2017 Jan; 27(1):115-125. PubMed ID: 27220852 [TBL] [Abstract][Full Text] [Related]
15. Fibrotic NASH in Individuals with Obesity: a Cross-sectional Analysis of the Prevalence of this Significant Milestone of Disease Progression and Accuracy of a Non-invasive Marker for its Screening. de Souza Echeverria L; Mounzer DLS; Gestic MA; Utrini MP; Chaim FDM; Callejas-Neto F; Chaim EA; Cazzo E Obes Surg; 2024 Feb; 34(2):389-395. PubMed ID: 38110785 [TBL] [Abstract][Full Text] [Related]
16. MACK-3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis. Chuah KH; Wan Yusoff WNI; Sthaneshwar P; Nik Mustapha NR; Mahadeva S; Chan WK Liver Int; 2019 Jul; 39(7):1315-1324. PubMed ID: 30825254 [TBL] [Abstract][Full Text] [Related]
17. Development and Validation of a Novel Scoring System for Noninvasive Nonalcoholic Steatohepatitis Detection in Bariatric Patients. Billeter AT; Wloka S; Behnisch R; Albrecht T; Roessler S; Goeppert B; Mueller S; Nickel F; Müller B Obes Facts; 2021; 14(5):490-500. PubMed ID: 34419953 [TBL] [Abstract][Full Text] [Related]
18. Development and validation of a noninvasive clinical scoring system to predict significant fibrosis in patients with nonalcoholic fatty liver disease. Jin W; Xu Y; Zhu W; Xia Z; Wu J Clin Chim Acta; 2021 Mar; 514():48-53. PubMed ID: 33333040 [TBL] [Abstract][Full Text] [Related]
19. Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis. Loomba R; Jain A; Diehl AM; Guy CD; Portenier D; Sudan R; Singh S; Faulkner C; Richards L; Hester KD; Okada L; Li XJ; Mimms L; Abdelmalek MF Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1867-1876.e3. PubMed ID: 30448594 [TBL] [Abstract][Full Text] [Related]
20. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease. Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]